![Phillip Mertz](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Phillip Mertz
Directeur/Bestuurslid bij ALPHA COGNITION INC.
Vermogen: 754 749 $ op 31-05-2024
Profiel
Phillip P.
Mertz is the founder of Secure Open Solutions.
He is currently the Chief Executive Officer at Subtle Technologies and the Director at Alpha Cognition, Inc. He previously worked as the Director at Alpha Cognition, Inc. Mr. Mertz completed his undergraduate degree at Harvard University in 2006.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
ALPHA COGNITION INC
1.40% | 29-08-2023 | 1 255 822 ( 1.40% ) | 754 749 $ | 31-05-2024 |
Actieve functies van Phillip Mertz
Bedrijven | Functie | Begin |
---|---|---|
ALPHA COGNITION INC. | Directeur/Bestuurslid | 22-03-2021 |
Secure Open Solutions | Oprichter | - |
Subtle Technologies | Algemeen Directeur | - |
Eerdere bekende functies van Phillip Mertz
Bedrijven | Functie | Einde |
---|---|---|
Alpha Cognition, Inc. /old/
![]() Alpha Cognition, Inc. /old/ Pharmaceuticals: MajorHealth Technology Alpha Cognition, Inc. engages in operation of a biopharmaceutical company focused on the development of novel therapies to treat diseases of the brain and spinal cord. It also provides research programs to find alternative ways of treating Alzheimer’s disease and Amyotrophic Lateral Sclerosis (ALS). The company is headquartered in Vancouver, Canada. | Directeur/Bestuurslid | - |
Opleiding van Phillip Mertz
Harvard University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
ALPHA COGNITION INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Alpha Cognition, Inc. /old/
![]() Alpha Cognition, Inc. /old/ Pharmaceuticals: MajorHealth Technology Alpha Cognition, Inc. engages in operation of a biopharmaceutical company focused on the development of novel therapies to treat diseases of the brain and spinal cord. It also provides research programs to find alternative ways of treating Alzheimer’s disease and Amyotrophic Lateral Sclerosis (ALS). The company is headquartered in Vancouver, Canada. | Health Technology |
Secure Open Solutions | |
Subtle Technologies |